Immunization Partners in Asia Pacific
Immunization Partners in Asia Pacific (IPAP) is a non-stock, non-profit organization committed to the development of a strong, progressive and dynamic movement that engages all stakeholders toward the realization of its vision through collaboration, cooperation, coordination, communication, consultation and partnership.
Spotlight
Reducing the burden of infant respiratory syncytial virus (RSV) in Asia Pacific
72% of infants hospitalized for respiratory syncytial virus (RSV) were born healthy. RSV impacts infant health, families, and economies across the region. "The Roadmap to Zero RSV Burden" whitepaper provides critical insights into the long-term consequences of RSV, the economic burden, and the urgent need for improved prevention strategies in all infants.
This whitepaper is an initiative by IPAP, with the support of Sanofi, and was developed with critical insights from over 20 key experts in public health policy, infant health and infectious diseases in Asia.
Click on the button below to download the whitepaper and get in touch with IPAP for interest to partner to advocate for better protection against RSV for all infants.
"A world where no person shall suffer from preventable diseases." This is IPAP's vision. Ambitious and yet not impossible. IPAP shall endeavor to engage all stakeholders in a reliable, effective and continuing advocacy campaign to increase, expand and improve immunization coverage in the region toward a genuine call for "Vaccination for Life".
